External radiation therapy employs advanced imaging and sophisticated treatment planning systems to arrive at optimal dose distribution. In this way it provides the best treatment for each patient. Similarly, appropriate assessment of the radiation dose deposited in the tumor and normal tissues is crucial for the success of targeted radiopharmaceutical therapies (RPT). Advances in imaging and biodistribution science make new approaches to RPT treatment planning possible. By administering the radionuclide dose, either pre-therapeutic (diagnostic) or the first therapeutic fraction of the cycle, and determining the patient's residence time (a measure of how long the radionuclide is retained in the body), the total therapeutic dose can be precisely adjusted to maximize the therapeutic effect and minimize toxicity. To offer the best possible treatment, prospective treatment planning should be performed, and a patient-specific maximally tolerated therapeutic radiation dose should be used. Furthermore, dosimetry should be performed on a regular basis throughout the treatment.
Goals
- To develop standard operation procedures (SOPs) for RPT dosimetry
- To support dosimetry for RPT Clinical Trials.
- To ultimately make RPT a dosimetry-based curative treatment approach
Current Chairperson
Emille Roncali, Ph.D., UC Davis, eroncali@ucdavis.edu
Telecommunications Schedule
The RPT Dosimetry Interest Group meets virtually via the Webex platform quarterly – on the 2nd Monday of March, June, September, and December at 3 p.m. ET.
Activities and Accomplishments
Access SOP's for dosimetry of Lu-177 and Ra-223 that have been developed for implementation in clinical trials through IROC & CIRO.
Interested in becoming a member of the RPT Dosimetry Interest Group?
Please Contact the Interest Group Coordinator:
Jacek Capala, Ph.D.
Radiation Research Program
National Cancer Institute
Division of Cancer Treatment & Diagnosis
Tel: 240-276-5706
Email: jacek.capala@nih.gov